Xenon Pharmaceuticals Inc (XENE) was Reiterated by Jefferies to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 13 from a previous price target of $10 . Jefferies advised their investors in a research report released on Apr 14, 2016.
Xenon Pharmaceuticals Inc (XENE) witnessed a volatile trading activity on Monday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $7.47 and reached the intraday high at $7.47. The bulls started the profit booking and pushed the shares to intraday low of $7.05. The trading session was marked by a volume range of 5,957 shares exchanging hands. The 52-week high of the shares is $17.5 and the 52-week low is $6.31. The market cap of the company stands at $103 M and there are 1,44,01,582 shares in public circulation.
In a different news, on Sep 24, 2015, Y. Paul Goldberg (VP of Clinical Development) sold 22,149 shares at $8.98 per share price.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company has built a core platform Extreme Genetics enabling the discovery of validated drug targets by studying rare human diseases with extreme traits including diseases caused by mutations in ion channels known as channelopathies. Its product pipeline includes Glybera which is a gene therapy approved in the EU for the treatment of patients with the orphan lipid disorder LPLD; TV-45070 which is a small-molecule inhibitor of the sodium channel Nav1.7; GDC-0276 which is a selective oral Nav1.7 small-molecule inhibitor being developed for the treatment of pain and XEN801 which is a selective small molecule inhibitor of SCD1 being developed for the treatment of dermatological disorders. FDA has granted fast track designations to TV-45070 for EM and to Glybera for LPLD and received orphan drug designation.